

Supplementary data

Table S1. eGFR decline and timeline

All variables are presented in n (%), unless otherwise specified

| Variable | Results |
|---|---|
| eGFR at start of GUIDE (ml/min/1.73m ²); mean (SD) (n=98*) No acute decline of renal function (n=84) Acute decline of renal function (n=14) | 12.3 (3.4) 12.7 (3.3) p=0.012 10.2 (3.7) |
| eGFR at start of first therapy (ml/min/1.73m ²); mean (SD) (n=35) | 8.1 (3,0) |
| Time between start of GUIDE and treatment choice in weeks; median (IQR) (n=74**) | 8.0 (9) Min: 1 Max: 34 |
| Time between treatment choice and start of first therapy in weeks; median (IQR) (n=31***) | 10 (20) Min: -3 Max: 53 |
| Time between treatment choice and start of the first therapy (n=76****) Insufficient (< 12 weeks) Sufficient (≥ 12 weeks) Still unknown at end of study (possibly sufficient) | 17 (22.4%) 46 (60.5%) 13 (17.1%) |
| eGFR at start of GUIDE (ml/min/1.73m ²); mean (SD) (n=62) Insufficient time between treatment choice and start of the first therapy Sufficient time between treatment choice and start of the first therapy | 10.1 (3.1) p=0.005 12.7 (3.0) |
| Time between start of GUIDE and start of first therapy in weeks; median (IQR) (n=31***) | 19 (21) Min: 2 Max: 57 |
| Time between start of first therapy and therapy-switch in weeks; median (IQR) (n=8) | 20.5 (28) Min: 5 Max: 49 |
| <p>* 2 patients, with an eGFR of 30 ml/min/1.73m² and 60 ml/min/1.73m² were excluded. They started the programme because of acute decline of renal function and because of a planned nephrectomy respectively. For 2 other patients the eGFR at start of GUIDE was unknown.</p> <p>** 10 patients that had an aberrant timeline (e.g. no home visit) because of their early choice for conservative treatment were excluded, as well as 8 patients (4 chose dialysis, 4 chose pre-emptive transplantation) that had made a treatment choice before, or in the same week as the start of GUIDE.</p> <p>*** 6 patients that had started therapy before start of GUIDE were excluded.</p> <p>**** 5 patients that had started therapy before start of GUIDE were excluded.</p> | |

Table S2. Treatment preference of patient, case manager and nephrologist
All variables are presented in n (%), unless otherwise specified

| | |
|--|------------|
| <i>Therapy preference of patient at the home visit* (n=102)</i> | |
| Home dialysis | 38 (37.3%) |
| In-centre dialysis | 29 (28.4%) |
| Conservative treatment | 12 (11.8%) |
| Transplantation | 7 (6.9%) |
| No preference/ doubt | 11 (10.8%) |
| Preference unknown | 5 (4.9%) |
| <i>Therapy preference of case manager after the home visit (n=102)</i> | |
| Suitable for home dialysis | 41 (40.2%) |
| Not suitable for home dialysis | 18 (17.6%) |
| Doubt about suitability of home dialysis | 25 (24.5%) |
| Preference unknown | 3 (2.9%) |
| No home visit* | 15 (14.7%) |
| <i>Therapy preference of nephrologist at time of referral (n=102)</i> | |
| Conservative treatment | 13 (12.7%) |
| Pre-emptive transplantation | 11 (10.8%) |
| Transplantation, with temporary home PD | 17 (16.7%) |
| Transplantation, with temporary home HD | 5 (4.9%) |
| Transplantation, with temporary CHD | 12 (11.8%) |
| Peritoneal dialysis | 26 (25.5%) |
| Home haemodialysis | 3 (2.9%) |
| In-centre haemodialysis | 15 (14.7%) |

* Patients that chose conservative treatment (n=10) or pre-emptive transplantation (n=5) at the start of the programme did not receive a home visit, their preference was deduced from their treatment choice.

Table S3. *Treatment recommendation or profile in MDM (n=102)*

All variables are presented in n (%), unless otherwise specified

| | |
|---|-------------------|
| Pre-emptive transplantation | 6 (5.9%) |
| Home dialysis | 54 (52.9%) |
| Transplantation + Home PD | 10 (9.8%) |
| Transplantation + Active HHD* | 6 (5.9%) |
| Transplantation + Passive HHD** | 0 |
| Transplantation + Home PD / Active HHD* | 9 (8.8%) |
| Transplantation + Home PD / Passive HHD** | 0 |
| Home PD | 13 (12.7%) |
| Active HHD* | 5 (4.9%) |
| Passive HHD** | 0 |
| Home PD / Active HHD* | 6 (5.9%) |
| Home PD / Passive HHD** | 2 (2.0%) |
| “Educate on all modalities” *** | 3 (3.0%) |
| In-centre dialysis | 32 (31.4%) |
| Transplantation + In-centre HD | 13 (12.7%) |
| In-centre HD | 19 (18.6%) |
| Conservative treatment | 10 (9.8%) |

* Active HHD: HHD with help from a patient’s partner or relatives

** Passive HHD: HHD with help of home care

*** This recommendation is not consistent with the GUIDE programme

Table S4. *Treatment choice (n=92*)*

All variables are presented in n (%), unless otherwise specified

| | |
|---------------------------------------|-------------------|
| Pre-emptive transplantation | 8 (8.7%) |
| Home dialysis | 31 (33.7%) |
| Transplantation + Home PD | 12 (13.0%) |
| Transplantation + HHD, active/passive | 5 (5.4%) |
| Home PD | 13 (14.1%) |
| HHD, active/passive | 1 (1.1%) |
| In-centre dialysis | 42 (45.7%) |
| Transplantation + In-centre HD | 17 (18.5%) |
| In-centre HD | 25 (27.2%) |
| Conservative treatment | 11 (12.0%) |

* 2 patients died before making a treatment choice, 8 patients had not made a treatment choice before 15 January 2015 (end of the study period)

Table S5. *First started therapy*

All variables are presented in n (%), unless otherwise specified

| Therapy | First started therapy (n=37) |
|-------------------------------|-------------------------------------|
| (Pre-emptive) transplantation | 2 (5.4%) |
| Home PD | 8 (21.6%) |
| Home HD | 0 |
| In-centre HD | 27 (73.0%) |